ClinicalTrials.gg
Not yet recruitingNCT07859189Updated Oct 5, 2026

Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery

A Phase 4 interventional study of Semaglutide weekly injection and Placebo in Morbid Obesity, sponsored by General Committee of Teaching Hospitals and Institutes, Egypt. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by General Committee of Teaching Hospitals and Institutes, Egypt · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Obesity, Morbid with a site in Egypt — 12 open to participants now, 16 under way, none of them phase 3. Obesity, Morbid · Egypt.

Planned enrollment
25th of 69
100 · median 90
Started
2026
with 9 others
Phase 4
6 of 76
5 open now
Primary completion
2028-10
later than 12 of 15 live
Registered
69th of 76
by date
Lead sponsor
8 of 76
General Committee of Teaching Hospitals and Institutes, Egypt

Among the 76 studies in Obesity, Morbid with a site in Egypt, this one is the 25th largest by planned enrollment of the 69 interventional ones that give a count, is one of 10 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 12 of the 15 other live ones, and was the 69th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

12 of the 76 studies in Obesity, Morbid with a site in Egypt are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Obesity, Morbid with a site in Egypt, or all of them as a file.
02

Study summary

Roughly one patient in five never reaches the expected weight loss after MBS, and long-term regain after SG is well documented. These patients are identifiable at the 12-month visit. Today they are watched, coached, and treated only when failure is established.

Whether the drug works in this group is no longer the question. BARI-STEP, published this year, randomized 70 patients with less than 20% weight loss after gastric bypass (including one-anastomosis) or sleeve gastrectomy, a mean of seven years after surgery, to semaglutide 2.4 mg or placebo: 18.0% loss versus 0.4% gain at 68 weeks, an adjusted difference of 19.1 percentage points. Its population was mixed, 55.7% with recurrent weight gain and 44.3% with suboptimal initial response, and its exploratory comparison found no difference in drug response between the two presentations. BARI-OPTIMISE showed the same direction with liraglutide, as did a randomized trial after gastric banding. Efficacy is settled.

Timing is not. BARI-STEP recruited patients a mean of seven years past surgery, after failure had hardened. No trial has tested treating at first recognition, the 12-month visit, against the current standard of structured waiting. The field's own reviews name timing and duration as the open questions. The 2024 IFSO international consensus reached 100% agreement that medication after MBS should generally be withheld until the weight plateau, and 100% agreement that adding it for a suboptimal response can then improve outcomes. That is exactly our immediate arm: treat at the plateau, at first recognition. The triggered arm is what clinics actually do: wait for established failure. Both positions rest on expert agreement, not on a trial. This is the randomized test of the consensus pathway. A registered open-label pilot starts tirzepatide at 12 or 18 months but is small, unblinded, and not a strategy comparison.

The 2026 consensus draws the line for us, and this protocol respects it. The Delphi panel defined surgical nonresponse as less than 10% TWL at 12 months, defined recurrent weight gain as regain of more than 25% of lost weight from nadir, and treated a 10% swing in %EWL from nadir as normal physiologic fluctuation. It gave no 12-month label at all to the patient with 10 to 19.9% TWL, and the IFSO Delphi consensus expects the weight nadir up to 2 years after surgery (Obes Surg 2023). So a patient at 14% TWL at one year may still be on the way down, and calling that failure would be wrong. The protocol therefore splits eligibility into two tiers. Below 10% TWL at 12 months: consensus-defined nonresponse, randomized at once, waiting adds nothing. 10 to below 20% TWL: randomized only after a documented plateau, defined in Section 4, with a hard cap at month 18 so waiting cannot drift into neglect. Randomization is stratified by tier, and results are reported by tier.

Read the detailed description

Both strategies have a real case, which is what makes this a trial and not a formality. For waiting: some patients improve in the second year without any drug, the drug is expensive, and a treat-everyone-at-12-months policy is unaffordable for most health systems, certainly ours. For immediate treatment: the BARI-STEP effect size, the metabolic cost of two lost years, and the risk that established regain is harder to reverse. Genuine equipoise, between strategies rather than between drug and nothing.

The design removes the ethical problem. Nobody is denied treatment. The triggered arm receives identical lifestyle support and blinded placebo, with guaranteed open-label semaglutide the moment the Delphi recurrence criteria are met, and unconditionally 12 months after randomization if response is still suboptimal. The question the trial asks is when, never whether.

The answer also bears on the operating room. Suboptimal responders are tomorrow's conversion candidates, and conversion carries higher morbidity for around 20% additional weight loss, which is why the field is already comparing drugs against conversion retrospectively. If early drug therapy keeps patients off the revision list, that is measured here as a secondary endpoint.

The health-economic answer may matter most. The triggered strategy tells us what fraction of suboptimal responders never need the drug at all, and what a targeted policy costs per percentage point of weight loss against a treat-all policy. For Egypt and every resource-limited system, that number decides what clinics will actually do. It fits the direction of the 2024 IFSO position on combining medication with surgery while telling payers when to start paying.

03

Conditions studied

  • Morbid Obesity

Browse trials for

Keywords

  • TOP-UP
  • semaglutide
  • suboptimal clinical response
  • primary metabolic and bariatric surgery
  • bariatric surgery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary laparoscopic SG or RYGB at our unit or a participating unit
  • %TWL less than 20% from the day of surgery, in one of two tiers. Tier A, surgical nonresponse: below 10% TWL at the 12-month visit; eligible immediately, randomization between months 12 and 14. Tier B, suboptimal response: 10 to below 20% TWL at the 12-month visit; eligible only after a documented plateau, randomization between months 12 and 18 (Plateau, defined. Two clinic weights at least 12 weeks apart differing by less than 2% of body weight, on the trial scale, with no change in treatment between them. This sits inside the swing the consensus panel itself called normal physiologic fluctuation. A Tier B patient still losing at month 12 is re-weighed at months 15 and 18. Reaching 20% TWL at any point means a good response and no enrollment. Still below 20% at month 18 means eligible regardless of plateau; the cap stops watchful waiting from becoming neglect.)
  • Anatomy assessed as normal in all: upper endoscopy for every patient, contrast study when symptoms suggest it
  • Able to self-inject and consent.

Exclusion criteria

Exclusion Criteria:

  • Any GLP-1-based therapy since surgery
  • Recurrent weight gain by the consensus definition, regain of more than 25% of the weight lost from nadir; these patients belong to RESURGE, not here
  • Anatomical abnormality explaining the poor response (these patients go to the revision pathway, not this trial)
  • Pregnancy or conception planned within the study (obesity pharmacotherapy is stopped at least 2 months before any planned conception, per current labeling and the 2026 Standards)
  • type 1 diabetes
  • medullary thyroid carcinoma or MEN2 history
  • pancreatitis history
  • untreated severe depression or active eating disorder on psychological review
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Immediate

    semaglutide 0.25, 0.5, 1.0, 1.7, 2.4 mg weekly in 4-weekly steps, then 2.4 mg or maximal tolerated dose, with reductions for tolerability permitted and recorded, to 12 months after randomization; in BARI-STEP six patients held reduced doses and the effect stood.

    Drug: Semaglutide weekly injection

  • Placebo comparator
    Triggered

    matched placebo on the identical schedule. Trigger 1: recurrent weight gain by the consensus definition, regain of more than 25% of the weight lost from nadir, confirmed on a second weight 4 weeks later, then immediate open-label semaglutide. Trigger 2: %TWL still below 20% at 12 months after randomization, then open-label semaglutide for the following 12 months.

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    semaglutide escalated to 2.4 mg weekly, continued for 12 months.

  • DrugPlacebo

    Criterion-triggered strategy: matched placebo with identical lifestyle support; guaranteed open-label semaglutide the moment consensus recurrence criteria are met, and in any case 12 months after randomization if response remains suboptimal.

06

What researchers measure

Primary outcomes

  1. Percentage total weight loss

    Measured in kilograms from pre-surgery weight at 12 months after randomization, same calibrated scale, morning, light clothing.

    Time frame: at 12 months

Secondary outcomes

  1. Percentage total weight loss

    Measured in kilograms at 6 and 24 months after randomization

    Time frame: 6, 24 months

  2. change in HbA1c

    An HbA1c level reflects your average blood sugar over the past two to three months, and any meaningful change typically takes at least 6 weeks to show because red blood cells live for about 3 months. Normal: Below 5.7% Prediabetes: 5.7% to 6.4% Diabetes: 6.5% or higher

    Time frame: 12, 24 months

  3. systolic and diastolic blood pressure

    Normal blood pressure is less than 120 mm Hg systolic and less than 80 mm Hg diastolic. Systolic (Top Number): Measures the pressure in your arteries when your heart beats and contracts. Diastolic (Bottom Number): Measures the pressure in your arteries when your heart rests between beats. • Normal: Less than 120 mm Hg systolic and less than 80 mm Hg diastolic. • Elevated: 120-129 mm Hg systolic and less than 80 mm Hg diastolic. • Stage 1 Hypertension (High Blood Pressure): 130-139 mm Hg systolic or 80-89 mm Hg diastolic. • Stage 2 Hypertension: 140 mm Hg or higher systolic, or 90 mm Hg or higher diastolic. • Hypertensive Crisis: Higher than 180 mm Hg systolic and/or higher than 120 mm Hg diastolic. This requires immediate emergency medical care

    Time frame: 12, 24 months

  4. total cholesterol, LDL, HDL, and triglycerides

    Normal adult values for a lipid panel are measured in milligrams per deciliter (mg/dL): • Total Cholesterol: Below 200 mg/dL is desirable. (Borderline high is 200-239 mg/dL, and high is 240 mg/dL and above.) • LDL ("Bad") Cholesterol: Below 100 mg/dL is optimal. (130-159 mg/dL is borderline high, and 160-189 mg/dL or higher is high.) • HDL ("Good") Cholesterol: 60 mg/dL and higher is protective. Levels below 40 mg/dL for men or below 50 mg/dL for women are considered low. • Triglycerides: Below 150 mg/dL is normal. (Borderline high is 150-199 mg/dL, and high is 200-499 mg/dL.)

    Time frame: 12, 24 months

  5. Hand-grip strength

    A hand grip strength test measures the maximum force of your hand and forearm muscles using a portable device called a handgrip dynamometer. Position yourself: Sit up straight with your feet flat on the floor. Place your arm by your side with your elbow bent at a 90-degree angle and your wrist in a neutral position. Hold the device: Adjust the handle so it fits comfortably in your hand. Squeeze hard: Squeeze the handles as hard as you can for about 3 to 5 seconds without moving your arm or resting the device against your body. Repeat trials: Take three measurements for each hand, resting for 15 to 30 seconds between attempts. Use either the highest score or the average of the trials. A normal hand grip strength score typically ranges from 40 to 56 kg (88 to 123 lbs) for adult men and 25 to 36 kg (55 to 79 lbs) for adult women aged 20-29.

    Time frame: 0, 12, 24 months

  6. change in IWQOL-Lite-CT total and domain scores

    The IWQOL-Lite-CT (Impact of Weight on Quality of Life-Lite Clinical Trials Version) score ranges from 0 to 100, where 100 represents the best possible quality of life and functioning (meaning zero weight-related impairment). • Total Score Range: 0-100 (higher = better quality of life) • Domain/Composite Scores: 0-100 • Raw scores are converted or transformed to a 0-100 scale for standard reporting.

    Time frame: 0, 12, 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartEst.
Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07859189
Lead sponsor
General Committee of Teaching Hospitals and Institutes, Egypt
Responsible party
Mohamed Hany Ashour (Professor, Surgeon, General Committee of Teaching Hospitals and Institutes, Egypt) — Principal investigator
First posted
Oct 5, 2026
Start date
Oct 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Mohamed Hany Ashour, Professor, MD
Contact
mohamed.ashour@alexu.edu.eg
+201002600970

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion